Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018
April 13 2018 - 8:02AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage
biotechnology company focused on the development of novel cancer
therapeutics, today announced that preclinical research for its
glutaminase inhibitor CB-839 will be shared as poster presentations
at the American Association for Cancer Research (AACR) Annual
Meeting 2018 in Chicago. CB-839 is a potent, selective,
orally bioavailable glutaminase inhibitor in Phase 2 trials.
The company and its academic collaborators will highlight
data of CB-839 in novel therapeutic combinations in preclinical
models of selected cancers.
“Tumor metabolism is a novel therapeutic approach that exploits
the way in which cancer cells utilize nutrients to grow and
survive,” said Susan Molineaux, PhD, President and Chief Executive
Officer of Calithera. “CB-839, a novel glutaminase inhibitor, has
the potential to be developed in combination with standard of care
cancer therapeutics such as CDK4/6 or PARP inhibitors to improve
patient outcomes.”
Preclinical data will be presented by Ethan Emberley, PhD, in a
poster titled, “The glutaminase inhibitor CB-839 synergizes with
CDK4/6 and PARP inhibitors in preclinical models,” on April 17,
2018 (Abstract #3509/6). Data will be presented demonstrating that
CB-839 synergizes with the CDK4/6 inhibitor palbociclib in
colorectal carcinoma, triple negative breast cancer (TNBC), and ER+
breast cancer cell lines, and enhances anti-tumor activity in both
an ER+ breast cancer and a colorectal cancer (CRC) xenograft tumor
model. CB-839 treatment in combination with the PARP
inhibitors niraparib and talazoparib has synergistic
anti-proliferative activity in TNBC, CRC, non-small cell lung
carcinoma, ovarian and prostate cancer cells. In vivo, the
combination of CB-839 with PARP inhibitors enhances anti-tumor
activity compared to single agent treatment in a CRC tumor
xenograft model.
Two additional posters will be presented by academic
collaborators:
- Suppression of clear cell ovarian carcinoma growth by
glutaminase-1 inhibitor as single agent and in combination with
PARP-1 inhibitorAbstract # LB-253/20Presenter: T. Li,
Laboratory of Othon Iliopoulos, Massachusetts General
HospitalTuesday April 17, 2018
- Combination treatment with CB-839 and romidepsin
induces apoptosis and suppresses cell viability in preclinical
models of chondrosarcomaAbstract #1329/7Presenter: T.N.
Sheikh, Laboratory of Gary Schwartz, Columbia UniversityMonday,
April 16, 2018
About CB-839
Calithera’s lead product candidate, CB-839, is a potent,
selective, reversible and orally bioavailable inhibitor of
glutaminase. CB-839’s onco-metabolism activity takes
advantage of the unique metabolic requirements of tumor cells and
cancer-fighting immune cells such as cytotoxic T-cells. It is
currently being evaluated in Phase 2 clinical trials in multiple
tumor types, in combination with standard of care agents.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused
on fighting cancer by discovering, developing, and commercializing
novel small molecule drugs that target tumor and immune cell
metabolism. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please
visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the
safety, tolerability and efficacy of CB-839, the overall
advancement of CB-839 in clinical trials, the unmet need in the
treatment of patients with advanced disease, and Calithera’s plans
to continue development of CB-839 in combination with PARP
inhibitors niraparib and talazoparib for the treatment of TNBC,
CRC, non-small cell lung carcinoma, ovarian and prostate cancer
cells. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release.
Such product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations
with respect to any of the foregoing matters may have a negative
effect on Calithera's stock price. Additional information
concerning these and other risk factors affecting Calithera's
business can be found in Calithera's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, and
other periodic filings with the Securities and Exchange Commission
at www.sec.gov. These forward-looking statements are not guarantees
of future performance and speak only as of the date hereof, and,
except as required by law, Calithera disclaims any obligation to
update these forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:Jennifer
McNealeyir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024